MaaT Pharma Presents Positive Results

• Positive efficacy and good safety results from 111 patients with acute graft-versus-host disease (aGvHD) treated with MaaT013 in Early Access Program presented at 2023 ASH Meeting
  Gastrointestinal overall response rate (GI-ORR) of 53% observed at day 28 positively and significantly impacted overall survival (OS) in responder patients
• OS results were even more pronounced (81% for responders and 8% for non-responders) in population matching patients in the Phase 3 ARES clinical trial (GI-ORR of 61% at day 28)
• Design of ongoing Phase 2b Trial in Europe evaluating MaaT033 in patients receiving allogeneic hematopoietic stem cell transplantation presented at 2023 ASH Meeting

Read the press release